Search all medical codes
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), influenza virus types a and b, and respiratory syncytial virus, multiplex amplified probe technique
CPT4 code
Name of the Procedure:
Infectious agent detection by nucleic acid (DNA or RNA); Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Influenza Virus Types A and B, and Respiratory Syncytial Virus (Multiplex Amplified Probe Technique)
Summary
This test uses advanced laboratory techniques to detect genetic material from multiple respiratory viruses, including COVID-19, Influenza A and B, and RSV, in a single sample. It is efficient and accurate at identifying the cause of respiratory infections.
Purpose
Medical Condition:
- Respiratory infections caused by SARS-CoV-2 (COVID-19), Influenza A and B, and Respiratory Syncytial Virus (RSV).
Goals:
- Rapidly identify the specific virus causing symptoms.
- Facilitate timely and appropriate treatment.
- Help prevent the spread of infectious respiratory diseases.
Indications
Symptoms:
- Fever, cough, shortness of breath, sore throat, body aches, fatigue, and other flu-like symptoms.
Patient Criteria:
- Individuals showing respiratory symptoms.
- People in close contact with confirmed cases.
- High-risk groups such as the elderly, immunocompromised, or those with chronic health conditions.
Preparation
Instructions:
- No specific dietary restrictions.
- Inform healthcare provider of current medications.
- Possibly provide a complete medical history and list of symptoms.
Tests and Assessments:
- No advanced testing needed prior to the procedure.
Procedure Description
- Sample Collection:
- A healthcare provider collects a sample using a nasal or throat swab.
- Laboratory Analysis:
- Samples are sent to a lab where nucleic acid amplification tests (NAAT) are performed.
- Multiplex Amplified Probe Technique:
- The technique uses probes to detect specific RNA or DNA sequences unique to SARS-CoV-2, Influenza A and B, and RSV within a single test run.
Tools and Technology:
- Swabs for sample collection.
- Laboratory equipment for NAAT and multiplex analysis.
Anesthesia:
- Not required.
Duration
- Sample collection takes a few minutes.
- Lab results are typically available within 24-48 hours.
Setting
- Outpatient clinic, hospital, or designated testing site.
Personnel
- Trained healthcare providers such as nurses or technicians for sample collection.
- Laboratory technicians and microbiologists for analysis.
Risks and Complications
Common Risks:
- Mild discomfort or gagging from the swab.
- Slight chance of nosebleed.
Rare Complications:
- Minimal risk of infection from the swab collection.
Benefits
- Rapid identification of the specific respiratory virus.
- Informs optimal treatment strategy.
- Assists in outbreak control and prevention measures.
Recovery
Post-Procedure Care:
- No specific aftercare required.
- Monitor for potential symptoms if not previously symptomatic.
Recovery Time:
- Immediate; there is no downtime required.
Follow-Up:
- Based on test results, follow healthcare provider's recommendations for treatment or isolation.
Alternatives
Other Options:
Individual tests for each virus.
Pros and Cons:
Pros of Multiplex Testing:
- Faster, comprehensive results from a single sample.
- Reduced need for multiple testing appointments.
Cons:
- May not be available in all healthcare settings.
Patient Experience
During the Procedure:
- Feelings:
- Discomfort but generally well-tolerated.
After the Procedure:
Experience:
- Relief in knowing prompt, accurate diagnostic information.
Pain Management:
- No pain management required.
- Communication with healthcare providers can help soothe discomfort during swab collection.